Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation.

Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation.

Rosiglitazone is a well-known anti-diabetic drug that increases insulin sensitivity via peroxisome proliferator-activated receptor γ (PPARγ) activation, but unfortunately it causes bone loss in animals and humans. A previous study showed that prolyl hydroxylase domain protein (PHD) plays a role in r...

Full description

Bibliographic Details
Main Authors: Ju-Hee Kang, Hyun Jeong Kwak, Hye-Eun Choi, Juyoung Kim, Sangmee Hong, Ok-Hee Kim, Byung Chul Oh, Hyae Gyeong Cheon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4587972?pdf=render

Internet

http://europepmc.org/articles/PMC4587972?pdf=render

Similar Items